NO20072887L - Forbindelser og sammensetninger som protein kinase inhibitorer - Google Patents
Forbindelser og sammensetninger som protein kinase inhibitorerInfo
- Publication number
- NO20072887L NO20072887L NO20072887A NO20072887A NO20072887L NO 20072887 L NO20072887 L NO 20072887L NO 20072887 A NO20072887 A NO 20072887A NO 20072887 A NO20072887 A NO 20072887A NO 20072887 L NO20072887 L NO 20072887L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- compositions
- protein kinase
- kinase inhibitors
- met
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62678504P | 2004-11-09 | 2004-11-09 | |
US70964805P | 2005-08-19 | 2005-08-19 | |
PCT/US2005/040372 WO2006052936A2 (en) | 2004-11-09 | 2005-11-07 | Compounds and compositions as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072887L true NO20072887L (no) | 2007-08-03 |
Family
ID=36337126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072887A NO20072887L (no) | 2004-11-09 | 2007-06-06 | Forbindelser og sammensetninger som protein kinase inhibitorer |
Country Status (17)
Country | Link |
---|---|
US (1) | US8101608B2 (de) |
EP (1) | EP1814545A4 (de) |
JP (1) | JP4917041B2 (de) |
KR (1) | KR20070084066A (de) |
AR (1) | AR053652A1 (de) |
AU (1) | AU2005304719B2 (de) |
BR (1) | BRPI0517968A (de) |
CA (1) | CA2583737C (de) |
GT (1) | GT200500321A (de) |
IL (1) | IL182687A0 (de) |
MA (1) | MA29216B1 (de) |
MX (1) | MX2007005547A (de) |
NO (1) | NO20072887L (de) |
RU (1) | RU2406725C2 (de) |
TN (1) | TNSN07176A1 (de) |
TW (1) | TW200631577A (de) |
WO (1) | WO2006052936A2 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005118551A2 (en) | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
US7314887B2 (en) | 2004-10-25 | 2008-01-01 | Ligand Pharmaceuticals, Inc. | Thrombopoietin activity modulating compounds and methods |
CA2602389A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Kinase inhibitors |
US7749530B2 (en) | 2005-07-13 | 2010-07-06 | Allergan, Inc. | Kinase inhibitors |
CA2602453A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Kinase inhibitors |
UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
WO2008022013A1 (en) * | 2006-08-11 | 2008-02-21 | Allergan, Inc. | Kinase inhibitors |
JP2010502741A (ja) | 2006-09-11 | 2010-01-28 | キュリス,インコーポレイテッド | Ptkインヒビターとしての亜鉛結合部分を含む置換2−インドリノン |
JP5568304B2 (ja) * | 2006-09-15 | 2014-08-06 | タイロジェネクス,インコーポレイテッド | キナーゼ阻害剤化合物 |
US20100087464A1 (en) * | 2006-10-06 | 2010-04-08 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
JP5577104B2 (ja) | 2007-03-14 | 2014-08-20 | エクセリクシス パテント カンパニー エルエルシー | ヘッジホッグ経路の阻害剤 |
WO2010008411A1 (en) | 2007-11-09 | 2010-01-21 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
JP5230755B2 (ja) | 2008-02-22 | 2013-07-10 | アイアールエム・リミテッド・ライアビリティ・カンパニー | c−kitおよびPDGFRキナーゼ阻害剤としてのヘテロ環化合物および組成物 |
JP5305704B2 (ja) * | 2008-03-24 | 2013-10-02 | 富士フイルム株式会社 | 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版 |
EP2300427A1 (de) * | 2008-05-05 | 2011-03-30 | Amgen Inc. | Harnstoffverbindungen als gamma-sekretase-modulatoren |
WO2009139834A1 (en) * | 2008-05-13 | 2009-11-19 | Poniard Pharmaceuticals, Inc. | Bioactive compounds for treatment of cancer and neurodegenerative diseases |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
EA029131B1 (ru) | 2008-05-21 | 2018-02-28 | Ариад Фармасьютикалз, Инк. | Фосфорсодержащие производные в качестве ингибиторов киназы |
WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
CN102115472B (zh) * | 2010-01-04 | 2013-12-04 | 深圳市天和医药科技开发有限公司 | 3-(2-吡咯亚甲基)氮杂吲哚啉-2-酮衍生物及其制法与应用 |
GB201014374D0 (en) * | 2010-08-27 | 2010-10-13 | Univ Greenwich | Novel hybrid compounds |
BR112013027734A2 (pt) | 2011-05-04 | 2017-08-08 | Ariad Pharma Inc | compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica |
KR101774861B1 (ko) | 2012-04-20 | 2017-09-05 | 안지 파마슈티컬 코퍼레이션 리미티드 | 퓨린 유도체의 사이클로프로판카르복실레이트 에스터 |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
EP2877211A4 (de) | 2012-07-25 | 2016-02-10 | Salk Inst For Biological Studi | Regelung der interaktion zwischen tam-liganden und lipidmembranen mit exponiertem phosphatidylserin |
US9296730B2 (en) | 2012-10-26 | 2016-03-29 | Regents Of The University Of Minnesota | Aurora kinase inhibitors |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2016161572A1 (en) * | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
US10487054B2 (en) | 2017-04-21 | 2019-11-26 | Regents Of The University Of Minnesota | Therapeutic compounds |
EA202091761A1 (ru) | 2018-01-31 | 2020-12-14 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия для лечения гастроинтестинальных стромальных опухолей |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
CN114615982A (zh) | 2019-08-12 | 2022-06-10 | 德西费拉制药有限责任公司 | 用于治疗胃肠道间质瘤的瑞普替尼 |
JP2022552444A (ja) | 2019-09-27 | 2022-12-15 | 武田薬品工業株式会社 | Hdac6阻害剤として有用な2-イソインドール-1,3,4-オキサジアゾール誘導体 |
CA3163053A1 (en) | 2019-12-30 | 2021-07-08 | Michael D. Kaufman | Amorphous kinase inhibitor formulations and methods of use thereof |
IL293864A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea |
CN114853735B (zh) * | 2022-07-06 | 2022-10-21 | 北京鑫开元医药科技有限公司 | 靶向泛素化降解trk的化合物及其制备方法、组合物和用途 |
CN114853736B (zh) * | 2022-07-06 | 2022-10-21 | 北京鑫开元医药科技有限公司 | 具有trk抑制活性的化合物、制备方法、组合物及其用途 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
WO2024054793A1 (en) | 2022-09-09 | 2024-03-14 | University Of Rochester | Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength |
CN118221652A (zh) * | 2022-12-19 | 2024-06-21 | 沈阳药科大学 | 一种吲哚-2-酮衍生物及其制备方法和用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565483A (en) | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
WO2000008202A2 (en) * | 1998-08-04 | 2000-02-17 | Sugen, Inc. | 3-methylidenyl-2-indolinone modulators of protein kinase |
WO1999048868A2 (en) * | 1998-03-26 | 1999-09-30 | Sugen, Inc. | Heterocyclic classes of compounds for the modulating tyrosine protein kinase |
CN1148350C (zh) * | 1998-05-28 | 2004-05-05 | 拜奥根有限公司 | 新型VLA-4抑制剂:oMePUPA-V |
WO1999061422A1 (en) * | 1998-05-29 | 1999-12-02 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
JP2002532493A (ja) * | 1998-12-17 | 2002-10-02 | エフ.ホフマン−ラ ロシュ アーゲー | Jnkプロテインキナーゼ阻害剤としての4−アリールオキシインドール |
GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
HU228979B1 (en) | 2000-02-15 | 2013-07-29 | Sugen | Pyrrole substituted 2-indolinone protein kinase inhibitors |
US6706709B2 (en) | 2000-06-02 | 2004-03-16 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
US20030119839A1 (en) * | 2001-12-13 | 2003-06-26 | Nan-Horng Lin | Protein kinase inhibitors |
TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
JP2006510727A (ja) | 2002-11-15 | 2006-03-30 | エクセリクシス, インク. | キナーゼモジュレーター |
-
2005
- 2005-11-04 GT GT200500321A patent/GT200500321A/es unknown
- 2005-11-07 WO PCT/US2005/040372 patent/WO2006052936A2/en active Application Filing
- 2005-11-07 EP EP05851419A patent/EP1814545A4/de not_active Withdrawn
- 2005-11-07 US US11/718,886 patent/US8101608B2/en not_active Expired - Fee Related
- 2005-11-07 RU RU2007121505/04A patent/RU2406725C2/ru not_active IP Right Cessation
- 2005-11-07 KR KR1020077010439A patent/KR20070084066A/ko active IP Right Grant
- 2005-11-07 BR BRPI0517968-8A patent/BRPI0517968A/pt not_active IP Right Cessation
- 2005-11-07 MX MX2007005547A patent/MX2007005547A/es active IP Right Grant
- 2005-11-07 AR ARP050104664A patent/AR053652A1/es unknown
- 2005-11-07 CA CA2583737A patent/CA2583737C/en not_active Expired - Fee Related
- 2005-11-07 JP JP2007540153A patent/JP4917041B2/ja not_active Expired - Fee Related
- 2005-11-07 AU AU2005304719A patent/AU2005304719B2/en not_active Ceased
- 2005-11-08 TW TW094139176A patent/TW200631577A/zh unknown
-
2007
- 2007-04-19 IL IL182687A patent/IL182687A0/en unknown
- 2007-05-08 TN TNP2007000176A patent/TNSN07176A1/fr unknown
- 2007-05-30 MA MA29953A patent/MA29216B1/fr unknown
- 2007-06-06 NO NO20072887A patent/NO20072887L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GT200500321A (es) | 2006-09-04 |
US8101608B2 (en) | 2012-01-24 |
US20080221192A1 (en) | 2008-09-11 |
TNSN07176A1 (en) | 2008-11-21 |
KR20070084066A (ko) | 2007-08-24 |
MX2007005547A (es) | 2007-07-05 |
EP1814545A2 (de) | 2007-08-08 |
RU2406725C2 (ru) | 2010-12-20 |
WO2006052936A3 (en) | 2006-10-26 |
JP4917041B2 (ja) | 2012-04-18 |
CA2583737C (en) | 2011-09-20 |
AR053652A1 (es) | 2007-05-16 |
TW200631577A (en) | 2006-09-16 |
CA2583737A1 (en) | 2006-05-18 |
JP2008519762A (ja) | 2008-06-12 |
RU2007121505A (ru) | 2008-12-20 |
IL182687A0 (en) | 2007-09-20 |
BRPI0517968A (pt) | 2008-10-21 |
AU2005304719A1 (en) | 2006-05-18 |
AU2005304719B2 (en) | 2009-07-23 |
EP1814545A4 (de) | 2009-06-10 |
WO2006052936A2 (en) | 2006-05-18 |
MA29216B1 (fr) | 2008-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072887L (no) | Forbindelser og sammensetninger som protein kinase inhibitorer | |
MX2009003649A (es) | Inhibidores de cinasa de proteina y metodos para utilizarlos. | |
NO20070160L (no) | Forbindelser og sammensetninger som proteinkinaseinhibitorer | |
TW200726766A (en) | Compounds and compositions as protein kinase inhibitors | |
NO20061074L (no) | Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet | |
ATE469151T1 (de) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
MX2008001969A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
PL1940844T3 (pl) | Związki i kompozycje jako inhibitory kinazy białkowej | |
WO2006101783A8 (en) | Compounds and compositions as protein kinase inhibitors | |
WO2006124731A3 (en) | Compounds and compositions as protein kinase inhibitors | |
NO20092612L (no) | Forbindelser og metode for kinasemodulering og indikasjoner for dette | |
NO20092138L (no) | Forbindelser og sammensetninger som proteinkinase inhibitorer | |
BRPI0415210A (pt) | compostos e composições como inibidores de proteìna cinase | |
NO20091989L (no) | Forbindelser som modulerer c-fms og/eller C-kit aktivitet og deres anvendelse | |
NO20065984L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
NO20091759L (no) | Forbindelser og sammensetninger som protein kinase inhibitorer | |
NO20065983L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
NO20063620L (no) | Arylanilinderivater som beta2 adrenergiske receptoragonister | |
BRPI0512422A (pt) | compostos e composições como inobidores da proteìna quinase | |
NO20084567L (no) | Polymorfe former av (2S) - (4E) -N-metyl-5-(3-isopropoksypyridin)yl]-4-penten-2-amin for behandling av sykdommer i sentralnervesystemet | |
MX2009006170A (es) | Compuestos y composiciones como inhibidores de cinasa. | |
BRPI0414049A (pt) | compostos e composições como inibidores de proteìna cinase | |
NO20071466L (no) | 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE | |
TH79792B (th) | สารประกอบและสารผสมที่เป็นสารยับยั้งโปรตีนไคเนส | |
TH79792A (th) | สารประกอบและสารผสมที่เป็นสารยับยั้งโปรตีนไคเนส |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |